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nomic evaluation of drug therapy. OBJECTIVES: This
was to assess the cost effectiveness of some antimicrobial
agents used in the treatment of sexually transmitted dis-
eases (STD). These include doxycycline versus tetracy-
cline for chlamydial infection, benzathine penicillin versus
procaine penicillin for syphilis, and ceftriaxone versus
spectinomycin for gonorrhoea. The choices were based on
standard treatment guidelines and observed prescrip-
tions. METHODS: Cost Effectiveness Analysis was used. 
The prescribed/dispensed prescriptions in STD clinic
between 1997 and 1999 were reviewed retrospectively.
Relevant information such as diagnosis, prescribed/
dispensed drugs, dosage, duration of therapy, laboratory
results, physician’s remarks among others were obtained
from patient case-notes and dispensed prescriptions. In
conjunction with these, time and motion studies and stan-
dard cost accounting technique were used. The cost per
deﬁned daily dose (DDD) and the cost of therapy for each
agent were calculated. The cost components include over-
head costs, and cost of drug/disposables acquisition. The
literature was reviewed for positive and negative conse-
quences of the considered therapeutic options. Improve-
ments in signs and symptoms as well as eradication of the
implicated organisms are the outcome measures. Decision
table was used in the effectiveness rating. These were
compared using chi square analysis. RESULTS: The
results showed that doxycycline, benzathine penicillin
and ceftriaxone were more effective than their respective
counterparts in the treatment of stated infections. For
example, doxycycline was N0.92 per unit effective while
tetracycline was N1.82 per unit effective. Tetracycline is
still widely used in the country. Alteration of some vari-
ables (cost and effectiveness rating) in favour of less cost
effective option did not change the conclusion conﬁrming
that doxycycline is truly more cost effective. CONCLU-
SION: It is concluded that tetracycline should no longer
be used except when doxycycline is not available. This
equally applies to benzathine penicillin and ceftriaxone
compared to their counterparts. However patients pecu-
liarities and contraindications need to be considered at all
times.
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OBJECTIVE: To determine the impact of Streptococcus
pyogenes (group A streptococcus, GAS) associated cel-
lulitis on hospital expenditure in the United States.
METHODS: This study analyzed data from the Health-
care Cost and Utilization Project (2000) funded by the
Agency for Healthcare Research and Quality. Hospital-
izations due to cellulitis were identiﬁed using ICD-9 codes
681–682 as principal diagnoses. We assumed that
30–50% of cellulitis-related hospitalizations were caused
by GAS. RESULTS: In 2000, there were approximately
110,000–183,000 hospitalizations due to GAS-associated
cellulitis. Adults aged 18–64 years accounted for 56% of
the hospitalizations, followed by the elderly (65 years 
and older, 36%) and children (<18 years, 8%). The most
common comorbid conditions associated with cellulitis
were hypertension (28%), diabetes mellitus (13%) and
congestive heart failure (10%). The mean and median
length of hospital stay for cellulitis were about ﬁve and
four days, respectively. Total annual hospitalization
charges for GAS-associated cellulitis were estimated at
$1.2–2.0 billion in year 2002 US dollars. Average charge
per hospital stay was about $10,500. CONCLUSIONS:
GAS-associated cellulitis represents a signiﬁcant eco-
nomic burden in the US. Total annual hospitalization
charges estimated for GAS-associated cellulitis are signif-
icantly higher than the recent estimate by the Institute of
Medicine (Vaccines for the 21st Century, A Tool for Deci-
sionmaking, 2000) for all GAS-associated hospitaliza-
tions (<$100 million).
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OBJECTIVES: Peginterferon alfa-2a (40KD)/ribavirin
(PEG) has been shown to produce a higher rate of sus-
tained virological response (SVR) than non-pegylated
combination therapy (non-PEG) in CHC, but the cost-
effectiveness of this improved efﬁcacy has not been
assessed. METHODS: We used a Markov model of
disease progression in which the cohorts of hepatitis C
virus (HCV) patients received PEG or non-PEG for either
48 or 24 weeks depending on genotype and liver histol-
ogy and were followed for their expected lifetime. The
reference patient was a 45-year-old male with CHC
without cirrhosis. The SVRs to PEG and non-PEG were
46% and 36% for HCV genotype 1 and 76% and 61%
for non-1, respectively. Quality of life and costs for each
health state were based on literature and on Italian treat-
ment patterns. Costs in 2002 Euros and beneﬁts were 
discounted at 3%. RESULTS: In HCV genotype 1, PEG
increases life expectancy (LY) by 0.78 years and quality-
adjusted life expectancy (QALY) by 0.67 years compared
to non-PEG. The incremental cost per QALY gained is
12,026 Euros. In HCV non-1 genotype patients, PEG
increases LY by 1.17 and QALY by 1.01 years in com-
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parison to non-PEG. The incremental cost per QALY
gained is €4289. The weighted average incremental 
cost-effectiveness ratio, using population-based HCV
genotype distribution estimates, for all genotypes was
€9473 per QALY. CONCLUSION: Peginterferon alfa-2a
(40KD)/ribavirin is a cost-effective therapy for treatment
of naive adults with CHC compared with standard inter-
feron alfa-2b/ribavirin, regardless of HCV genotype.
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OBJECTIVES: Due to the high prevalence of hepatitis B
infection in some Asian countries and the associated 
morbidity and mortality, widespread treatment of chronic
hepatitis B treatment would have major public health
implications in these countries. We evaluated the cost-
effectiveness of 3 treatment regimens for chronic hepati-
tis B (interferon-alpha for 16 weeks, lamivudine for 
1 year, and lamivudine for 3 years) vs. no treatment 
in Taiwan, where government-sponsored universal 
health insurance have been implemented since 1995.
METHODS: We followed international guidelines on
cost-effectiveness analysis and constructed a Markov
model to project disease progression and health care
expenditure among hypothetical cohorts of 30-year-old
chronic hepatitis B patients. We adopted the societal 
perspective and a 70-year time frame since treatment 
initiation. Taiwan-speciﬁc disease, quality-of-life, and
costs information was used for virtually all model para-
meters. Outcome of interest was the Incremental Cost-
Effectiveness Ratio (ICER) in Taiwan Dollar (TWD,
US$1 = 34.41TWD on January 13, 2003) per QALY.
RESULTS: For a 30-year-old chronic hepatitis B patient
under base-case assumption, projected increase in life
expectancy was 1.84 years, 2.01 years, and 3.9 years if
s/he was treated with interferon, lamivudine for one year,
and lamivudine for three years, respectively. ICERs
(TWD/QALY) with 3% annual discount rate were 34,700
for interferon, 17,400 for 1 year of lamivudine, and
46,200 for 3 years of lamivudine. Monte Carlo simula-
tion showed robust results with respect to a wide range
of parameter assumptions and each of the three treatment
regimens could result in costs-savings. In multi-way sen-
sitivity analysis, the upper range of 95% of the ICERs
(with 3% annual discount rate) were 204,100 for inter-
feron, 127,800 for 1 year of lamivudine, and 197,900 for
3 years of lamivudine. CONCLUSIONS: Using lamivu-
dine to treat of chronic hepatitis B among young adults
in Taiwan would result in substantial gain in life
expectancy.
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OBJECTIVES: Approximately 350 million patients have
Chronic HBV infection worldwide. In Brazil there are
more than 3 million chronically infected with HBV. HBV
infection leads to chronic liver disease states such as cir-
rhosis, hepatocarcinoma and the need for transplanta-
tion. There is little published data on the cost of HBV in
Brazil. The aim of this study is to investigate treatments
patterns, medical resource use and treatment costs for
each state of HBV infection. METHODS: A question-
naire was developed and a physician survey conducted to
obtain information about the treatment patterns for
Chronic HBV in Brazil. Data were collected from physi-
cians in seven hospitals, across three different regions of
Brazil. Cost information was derived predominantly from
the government pay schedule; private hospital services
and pharmacy cost tables for medical care in Brazil.
RESULTS: Patients were separated into those managed
with and without antiviral medications. Lamivudine 
and Interferon alfa 2-B were the most common used
antiviral agents, with a cost of R$921.17 (year patient)
and R$15,424 (year/patient) respectively. The expected
annual costs per patient were: R$7,561 (R$1,030,
R$17,374) for chronic hepatitis B with antiviral medica-
tion, R$326 (R$212, R$512) for chronic hepatitis B
without antiviral medication, R$6,279 (R$1,030,
R$17,377) for compensated cirrhosis with antiviral 
medication, R$384 (R$212, R$555) for compensated 
cirrhosis without antiviral medication, R$16,522
(R$3,392, R$44,336) for decompensated cirrhosis,
R$39,895 (R$38,678, R$41,112) for liver transplanta-
tion, R$29,858 (R$26,513, R$33,202) for transplant
care after the ﬁrst year and R$2,382 (R$1,731, R$3,032)
for hepatocellular carcinoma. CONCLUSIONS: These
cost data can be used to model disease burden in Brazil.
Cost of antiviral medications inﬂuence disease costs in
chronic HBV and compensated cirrhosis states. Costs
increase dramatically in the more advanced health states,
and indicate that slowing progression to these states may
be cost savings. One USD = 3 R$ at the moment of the
survey.
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